Jyothy Labs raises buyback price to 240 rupees

Jyothy Labs increased its share buyback price to ₹240 from ₹215, reducing the total share count to 61.25 lakh. This revised offer represents 1.67% of the company's paid-up equity capital. The revised total outlay remains approximately ₹14.7 crore. This matters because it establishes a 15% premium valuation floor, directly countering recent EBITDA margin compression to 2.5% in Q2 FY27. I am watching the Q3 FY27 earnings call in January 2027 for management's commentary on raw material cost stabilization and the sequential operating margin recovery for core brands like Ujala and Exo. The market typically interprets a buyback price hike as an aggressive capital return signal. What the consensus misses is the strategic nuance of this specific move. First, the ₹14.7 crore total outlay is minuscule compared to the company's ~₹997 crore cash reserve, making this a symbolic price-support mechanism rather than meaningful capital redistribution. Second, offering a 15% premium at ₹240 signals management's conviction in the intrinsic value floor, countering the narrative of a 42% drop from its 52-week high. Third, it buys the promoters time to execute their portfolio transformation without facing shareholder pressure during a temporary profitability trough. The market misprices this as a massive liquidity event, ignoring it is a highly efficient, low-cost signaling tool to stabilize the stock during margin headwinds. Accumulate on valuation floor support for long-term FMCG margin recovery. Disclosure: I do not hold positions in this stock. This is for educational purposes only and does not constitute investment advice. JYOTHYLAB